100% Original Multimodal Anesthesia - 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]- 5,6,7,7a-tetrahydrothieno[3,2-c]pyridin-2 (4h)-one – JIN DUN

5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]- 5,6,7,7a-tetrahydrothieno[3,2-c]pyridin-2 (4h)-one is used as the intermediate of Prasugrel .
Prasugrel is a thiophenopyridine antiplatelet developed by Eli Lilly and daiichisankyo, a Japanese pharmaceutical manufacturer. It is a precursor drug. It forms an active molecule after metabolism through cytochrome P450 in the liver and combines with platelet P2Y12 receptor to exert an active against platelet aggregation. Clinical studies have proved that 60 mg dose has better anticoagulant effect than 300 mg standard dose and 600 mg increased dose of clopidogrel, which can reduce the comprehensive risk of heart attack, stroke and death due to heart disease by 20%, and has fast effect, good curative effect, good drug resistance and bioavailability, and low toxicity.